|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang L, Lo CH, He X, Hang D, Wang M, Wu K,
Chan AT, Ogino S, Giovannucci EL and Song M: Risk factor profiles
differ for cancers of different regions of the colorectum.
Gastroenterology. 159:241–256.e13. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cree IA, Indave Ruiz BI, Zavadil J, McKay
J, Olivier M, Kozlakidis Z, Lazar AJ, Hyde C, Holdenrieder S,
Hastings R, et al: The international collaboration for cancer
classification and research. Int J Cancer. 148:560–571. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beck DE: Surgical management of colon and
rectal cancer. Ochsner J. 4:156–162. 2002.PubMed/NCBI
|
|
5
|
Cremolini C, Loupakis F, Antoniotti C,
Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M,
Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment of patients with metastatic
colorectal cancer: Updated overall survival and molecular subgroup
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.
16:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kastrinos F, Kupfer SS and Gupta S:
Colorectal cancer risk assessment and precision approaches to
screening: Brave new world or worlds apart? Gastroenterology.
164:812–827. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sadahiro S, Suzuki T, Ishikawa K, Nakamura
T, Tanaka Y, Masuda T, Mukoyama S, Yasuda S, Tajima T, Makuuchi H
and Murayama C: Recurrence patterns after curative resection of
colorectal cancer in patients followed for a minimum of ten years.
Hepatogastroenterology. 50:1362–1366. 2003.PubMed/NCBI
|
|
8
|
Fakih GM: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sepulveda AR, Hamilton SR, Allegra CJ,
Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C,
Lindor NM, Minsky BD, et al: Molecular biomarkers for the
evaluation of colorectal cancer: Guideline from the American
society for clinical pathology, college of American pathologists,
association for molecular pathology, and American society of
clinical oncology. J Mol Diagn. 19:187–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Gao W, Shi X, Ding J, Liu W, He H,
Wang K and Shao F: Chemotherapy drugs induce pyroptosis through
caspase-3 cleavage of a gasdermin. Nature. 547:99–103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fink SL and Cookson BT:
Caspase-1-dependent pore formation during pyroptosis leads to
osmotic lysis of infected host macrophages. Cell Microbiol.
8:1812–1825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding J, Wang K, Liu W, She Y, Sun Q, Shi
J, Sun H, Wang DC and Shao F: Pore-forming activity and structural
autoinhibition of the gasdermin family. Nature. 535:111–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi J, Zhao Y, Wang K, Shi X, Wang Y,
Huang H, Zhuang Y, Cai T, Wang F and Shao F: Cleavage of GSDMD by
inflammatory caspases determines pyroptotic cell death. Nature.
526:660–665. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Al Mamun A, Mimi AA, Aziz MA, Zaeem M,
Ahmed T, Munir F and Xiao J: Role of pyroptosis in cancer and its
therapeutic regulation. Eur J Pharmacol. 910:1744442021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan G, Huang C, Chen J and Zhi F: HMGB1
released from GSDME-mediated pyroptotic epithelial cells
participates in the tumorigenesis of colitis-associated colorectal
cancer through the ERK1/2 pathway. J Hematol Oncol. 13:1492020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang Z, Ji L, Han M, Xie J, Zhong F, Zhang
X, Su Q, Yang Z, Liu Z, Gao H and Jiang G: Pyroptosis is involved
in the inhibitory effect of FL118 on growth and metastasis in
colorectal cancer. Life Sci. 257:1180652020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo J, Zheng J, Mu M, Chen Z, Xu Z, Zhao
C, Yang K, Qin X, Sun X and Yu J: GW4064 enhances the
chemosensitivity of colorectal cancer to oxaliplatin by inducing
pyroptosis. Biochem Biophys Res Commun. 548:60–66. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Jensen MA and Zenklusen JC: A
practical guide to the cancer genome atlas (TCGA). Methods Mol
Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marisa L, de Reyniès A, Duval A, Selves J,
Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D,
Ayadi M, et al: Gene expression classification of colon cancer into
molecular subtypes: Characterization, validation, and prognostic
value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karki R and Kanneganti TD: Diverging
inflammasome signals in tumorigenesis and potential targeting. Nat
Rev Cancer. 19:197–214. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang B and Yin Q: AIM2 inflammasome
activation and regulation: A structural perspective. J Struct Biol.
200:279–282. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Man SM and Kanneganti TD: Regulation of
inflammasome activation. Immunol Rev. 265:6–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hartigan JA and Wong MA: Algorithm AS 136:
A K-means clustering algorithm. J R Stat Soc C (Appl Stat).
28:100–108. 1979.
|
|
24
|
Wilkerson MD and Hayes DN:
ConsensusClusterPlus: A class discovery tool with confidence
assessments and item tracking. Bioinformatics. 26:1572–1573. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yao H, Wu H and Liu Y: Improvement of
prognostic and predictive network of colorectal cancer based upon
the 8th edition of AJCC colorectal cancer staging system. Zhonghua
Wei Chang Wai Ke Za Zhi. 20:24–27. 2017.(In Chinese). PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Charoentong P, Angelova M, Efremova M,
Gallasch R, Hackl H, Galon J and Trajanoski Z: Bioinformatics for
cancer immunology and immunotherapy. Cancer Immunol Immunother.
61:1885–1903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pitt JM, Marabelle A, Eggermont A, Soria
JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment:
Removing obstruction to anticancer immune responses and
immunotherapy. Ann Oncol. 27:1482–1492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cristescu R, Mogg R, Ayers M, Albright A,
Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al:
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based
immunotherapy. Science. 362:eaar35932018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Asaoka Y, Ijichi H and Koike K: PD-1
blockade in tumors with mismatch-repair deficiency. N Engl J Med.
373:19792015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chénard-Poirier M and Smyth EC: Immune
checkpoint inhibitors in the treatment of gastroesophageal cancer.
Drugs. 79:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ewing I, Hurley JJ, Josephides E and
Millar A: The molecular genetics of colorectal cancer. Frontline
Gastroenterol. 5:26–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia X, Wang X, Cheng Z, Qin W, Lei L,
Jiang J and Hu J: The role of pyroptosis in cancer: Pro-cancer or
pro-‘host’? Cell Death Dis. 10:6502019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei Q, Zhu R, Zhu J, Zhao R and Li M:
E2-induced activation of the NLRP3 inflammasome triggers pyroptosis
and inhibits autophagy in HCC cells. Oncol Res. 27:827–834. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miguchi M, Hinoi T, Shimomura M, Adachi T,
Saito Y, Niitsu H, Kochi M, Sada H, Sotomaru Y, Ikenoue T, et al:
Gasdermin C is upregulated by inactivation of transforming growth
factor β receptor type II in the presence of mutated Apc, promoting
colorectal cancer proliferation. Plos One. 11:e01664222016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Loveless R, Bloomquist R and Teng Y:
Pyroptosis at the forefront of anticancer immunity. J Exp Clin
Cancer Res. 40:2642021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schlößer HA, Theurich S,
Shimabukuro-Vornhagen A, Holtick U, Stippel DL and von
Bergwelt-Baildon M: Overcoming tumor-mediated immunosuppression.
Immunotherapy. 6:973–988. 2014. View Article : Google Scholar
|
|
44
|
Göschl L, Scheinecker C and Bonelli M:
Treg cells in autoimmunity: From identification to Treg-based
therapies. Semin Immunopathol. 41:301–314. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Van der Jeught K, Xu HC, Li YJ, Lu XB and
Ji G: Drug resistance and new therapies in colorectal cancer. World
J Gastroenterol. 24:3834–3848. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang TL, Diaz LA Jr, Romans K, Bardelli A,
Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, et
al: Digital karyotyping identifies thymidylate synthase
amplification as a mechanism of resistance to 5-fluorouracil in
metastatic colorectal cancer patients. Proc Natl Acad Sci USA.
101:3089–3094. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng C and Tan Z: A novel identified
pyroptosis-related prognostic signature of colorectal cancer. Math
Biosci Eng. 18:8783–8796. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li R, Zhang S and Liu G: Identification
and validation of a pyroptosis-related prognostic model for
colorectal cancer. Funct Integr Genomics. 23:212022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen M, Zhang J, Lin X, Zhu X and Xie T: A
pyroptosis-related prognosis model to predict survival in
colorectal cancer patients. Int J Clin Exp Pathol. 15:168–182.
2022.PubMed/NCBI
|
